Main Page
Deanship
The Dean
Dean's Word
Curriculum Vitae
Contact the Dean
Vision and Mission
Organizational Structure
Vice- Deanship
Vice- Dean
KAU Graduate Studies
Research Services & Courses
Research Services Unit
Important Research for Society
Deanship's Services
FAQs
Research
Staff Directory
Files
Favorite Websites
Deanship Access Map
Graduate Studies Awards
Deanship's Staff
Staff Directory
Files
Researches
Contact us
عربي
English
About
Admission
Academic
Research and Innovations
University Life
E-Services
Search
Deanship of Graduate Studies
Document Details
Document Type
:
Thesis
Document Title
:
MCHANISM OF ACQUIRED RESISTANCE TO ABT-199 IN MV4-11 CELL LINE
آلية المقاومة المكتسبة ضد علاج ابت-199 (فينيتوكلاكس) في السلالة الخلوية ام في 4-11
Subject
:
College of Applied Medical Sciences
Document Language
:
Arabic
Abstract
:
Venetoclax (ABT-199) is a highly selective B-cell lymphoma 2 (BCL-2) inhibitor. It recently received accelerated US FDA approval for use in combination with hypomethylating agents or with low-dose cytarabine in elderly or acute myeloid leukemia (AML) patients unfit for other treatment. Venetoclax-based AML treatment showed a tolerable safety and favorable overall response rate in elderly patients with AML. The acquisition of resistance to Venetoclax in AML is the leading cause of treatment failure. Resistance to ABT-199 is generally attributed to increased levels of MCL-1 and/or BCL-XL, or acquisition of mutations in the BCL-2 gene. To study the mechanisms of acquired ABT-199 resistance, we created ABT-199 resistant MV4-11 cells by treating MV4-11 cells with incremental doses of the drug starting from 1nM to 100nM for eight weeks. Five ABT-199 resistant MV4-11 clones were then isolated after culturing the cells in methylcellulose based medium. (MV4-11 ABT-199/R1 through 5). The MV4-11 ABT-199R clones demonstrated 160 – 350-fold higher resistance to ABT-199 than the parental cells. Microarray-based gene expression profiling of the two resistant clones (ABT-199/R1, ABT-199/R2) in comparison to the parental cell line (MV4-11) showed downregulation of BAX gene expression. We subsequently performed genomic DNA PCR for the BAX gene that revealed a micro-deletion in the resistant clones that included the promoter region and the first three exons of the BAX gene. Due to BAX gene deletion, the resistant clones also demonstrated co-resistance to ABT-737 (BCL-2 and BCL-XL inhibitor), S63845 (MCL-1 inhibitor), and S55746 (BCL-2 inhibitor). In summary, we are reporting a novel mechanism of Venetoclax resistance by genomic deletion of BAX in MV4-11 cells. As a result of BAX gene deletion, the inhibitors of BCL-2, BCL-XL, and MCL-1 are rendered ineffective in inducing apoptosis. Alternative mechanisms of apoptosis induction need to be explored to overcome BAX deletion-induced resistance. Screening of BAX gene locus in patients showing ABT-199 resistance is advised.
Supervisor
:
Dr. Farid Yassin
Thesis Type
:
Master Thesis
Publishing Year
:
1441 AH
2020 AD
Added Date
:
Monday, June 29, 2020
Researchers
Researcher Name (Arabic)
Researcher Name (English)
Researcher Type
Dr Grade
Email
عمر عبد الله اللحياني
Allehyani, Omar Abdullah
Researcher
Master
Files
File Name
Type
Description
46541.pdf
pdf
Back To Researches Page